relugolix (ORGOVYX) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Relugolix, sold under the brand names Orgovyx and Relumina among others, is a gonadotropin-releasing hormone antagonist medication which is used in the treatment of prostate cancer in men and uterine fibroids in women. It is taken by mouth.   Wikipedia

Chemistry

  • SMILES: CONC(=O)Nc1ccc(-c2sc3c(c2CN(C)C)c(=O)n(-c2ccc(OC)nn2)c(=O)n3Cc2c(F)cccc2F)cc1
  • InChIKey: AOMXMOCNKJTRQP-UHFFFAOYSA-N
  • Mol. Mass: 623.64
  • ALogP: 3.75
  • ChEMBL Molecule:
    relugolix  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$57.7127
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

( relugolix (ORGOVYX), estradiol (progynon depot), norethindrone - other name: relugolix/e2/neta fdc )

Alternative names

1-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno(2,3-d)pyrimidin-6-yl)phenyl)-3-methoxyurea | relugolix | tak385 | tak 385 | tak-385

Organizations (17)

Research & Development (16)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (1)


 

Prostatic Neoplasms (approved 2020)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Androgens (Phase 1)

Contraception (Phase 3)

Endometriosis (Phase 3)

Healthy Volunteers (Phase 1)

Leiomyoma (Phase 3)

Menorrhagia (Phase 3)

Pain (Phase 3)

Prostatic Neoplasms (Phase 4)

Prostatic Neoplasms, Castration-Resistant (Phase 1)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 36
  • # of Trial Organizations: 16

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue